School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, P.R. China.
ACS Appl Mater Interfaces. 2021 Aug 25;13(33):39934-39948. doi: 10.1021/acsami.1c11327. Epub 2021 Aug 16.
There are two severe obstacles in cancer immunotherapy. The first is that the low response rate challenges the immune response owing to the immunosuppressive tumor microenvironment (ITM) and poor immunogenicity of the tumor. The second obstacle is that the dense and intricate pathophysiology barrier seriously restricts deep drug delivery in solid tumors. A laser/glutathione (GSH)-activatable nanosystem with tumor penetration for achieving highly efficient immunotherapy is reported. The core of the nanosystem was synthesized by coordinating zinc ions with GSH-activatable oxaliplatin (OXA) prodrugs and carboxylated phthalocyanine. Such an OXA/phthalocyanine-based coordination polymer nanoparticle (OPCPN) was wrapped by a phospholipid bilayer and NTKPEG. NTKPEG is a PEGylated indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor prodrug containing a thioketal (TK) linker, which was modified on the OPCPN (OPCPN@NTKPEG). Upon the laser irradiation tumor site, ROS production of the OPCPN@NTKPEG triggers cleavage of NTKPEG by degradation of TK for promoted tumor penetration and uptake. OXA, phthalocyanine, and IDO1 inhibitor were released by the intracellular high-level GSH. OXA inhibits cell growth and is combined with photodynamic therapy (PDT) to induce immunogenic cell death (ICD). The IDO1 inhibitor reversed the ITM by suppressing IDO1-mediated Trp degradation and exhaustion of cytotoxic T cells. Laser/GSH-activatable drug delivery was more conducive to enhancing ICD and reversing ITM in deep tumors. Chemo-PDT with OPCPN@NTKPEG significantly regressed tumor growth and reduced metastasis by improved cancer immunotherapy.
癌症免疫疗法存在两个严重障碍。第一个障碍是由于免疫抑制性肿瘤微环境(ITM)和肿瘤的低免疫原性,低反应率挑战了免疫反应。第二个障碍是致密而复杂的病理生理屏障严重限制了实体瘤中药物的深层输送。据报道,一种具有肿瘤穿透能力的激光/谷胱甘肽(GSH)激活纳米系统可实现高效的免疫治疗。纳米系统的核心是通过将锌离子与 GSH 激活的奥沙利铂(OXA)前药和羧基酞菁配位合成的。这种 OXA/酞菁基配位聚合物纳米颗粒(OPCPN)被磷脂双层和 NTKPEG 包裹。NTKPEG 是一种含有硫缩酮(TK)连接物的聚乙二醇化吲哚胺 2,3-双加氧酶 1(IDO1)抑制剂前药,修饰在 OPCPN(OPCPN@NTKPEG)上。当激光照射肿瘤部位时,OPCPN@NTKPEG 的 ROS 产生会触发 TK 的降解,从而通过促进肿瘤穿透和摄取来触发 NTKPEG 的裂解。细胞内高水平的 GSH 释放出 OXA、酞菁和 IDO1 抑制剂。OXA 抑制细胞生长,并与光动力疗法(PDT)结合诱导免疫原性细胞死亡(ICD)。IDO1 抑制剂通过抑制 IDO1 介导的色氨酸降解和细胞毒性 T 细胞耗竭来逆转 ITM。激光/GSH 激活的药物输送更有利于增强 ICD 和逆转深部肿瘤中的 ITM。用 OPCPN@NTKPEG 进行化疗-PDT 可通过改善癌症免疫治疗显著抑制肿瘤生长和减少转移。